RI Related News

비회원이 작성한 글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.

List Next Prev
게시글 내용
TRIUMF Enters Collaboration with Fusion Pharmaceuticals to Boost Production of Actinium-225, a Cancer-Fighting Medical Isotope

TRIUMF, Canada’s particle accelerator centre, announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies.


An alpha-emitting isotope with a short half-life, actinium-225 can be combined with a molecular agent that specifically targets cancer cells, seeking out and destroying the cancer while leaving the surrounding tissue unharmed. The new collaboration will enable TRIUMF to significantly increase production and delivery of actinium-225.


To read more please visit:


Source: TRIUMF Innovations